Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MYC rearrangement + BCL2 rearrangement
i
Other names:
MYC, bHLHe39, c-Myc, MYCC, V-myc avian myelocytomatosis viral oncogene homolog, BCL2, Bcl-2, PPP1R50, B-cell CLL/lymphoma 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4609
;
596
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
MYC overexpression (18)
BCL2 overexpression (17)
MYC expression (9)
BCL2 expression (9)
BCL2 expression + MYC expression (8)
MYC overexpression + BCL2 overexpression (7)
BCL2 positive (7)
MYC positive (3)
MYC expression + BCL2 expression (2)
MYC underexpression (2)
miR-17-HG overexpression + MYC positive (2)
BCL2 overexpression + MCL1 overexpression (2)
BCL2 underexpression (2)
BCL2 overexpression + MYC overexpression (1)
BTK expression + BCL2 expression + MYC expression (1)
BTK expression + MYC expression (1)
CHEK1 overexpression + MYC overexpression (1)
MYC expression + BCL2 expression + BCL6 expression (1)
MYC expression + MCL1 expression (1)
MYC negative (1)
MYC positive + BCL2 positive (1)
MYC positive + BCL2 positive + BCL6 positive (1)
MYC expression + PAICS expression (1)
OTUD6B expression + MYC expression (1)
miR-17-HG expression + MYC positive (1)
BCL2 overexpression + CCND1 overexpression (1)
BCL2 overexpression + MCL1 expression (1)
BCL2 overexpression + MCL1 underxpression + BCL2L1 underexpression (1)
BCL2 positive + LGALS3 expression (1)
BTK expression + BCL2 expression (1)
CASP3 overexpression + BCL2 negative (1)
CASP3 underexpression + BCL2 positive (1)
CD20 expression + PAX5 expression + BCL2 expression (1)
CD22 underexpression + BCL2 overexpression (1)
BCL2 positive + IGH positive (0)
MYC overexpression (18)
BCL2 overexpression (17)
MYC expression (9)
BCL2 expression (9)
BCL2 expression + MYC expression (8)
MYC overexpression + BCL2 overexpression (7)
BCL2 positive (7)
MYC positive (3)
MYC expression + BCL2 expression (2)
MYC underexpression (2)
miR-17-HG overexpression + MYC positive (2)
BCL2 overexpression + MCL1 overexpression (2)
BCL2 underexpression (2)
BCL2 overexpression + MYC overexpression (1)
BTK expression + BCL2 expression + MYC expression (1)
BTK expression + MYC expression (1)
CHEK1 overexpression + MYC overexpression (1)
MYC expression + BCL2 expression + BCL6 expression (1)
MYC expression + MCL1 expression (1)
MYC negative (1)
MYC positive + BCL2 positive (1)
MYC positive + BCL2 positive + BCL6 positive (1)
MYC expression + PAICS expression (1)
OTUD6B expression + MYC expression (1)
miR-17-HG expression + MYC positive (1)
BCL2 overexpression + CCND1 overexpression (1)
BCL2 overexpression + MCL1 expression (1)
BCL2 overexpression + MCL1 underxpression + BCL2L1 underexpression (1)
BCL2 positive + LGALS3 expression (1)
BTK expression + BCL2 expression (1)
CASP3 overexpression + BCL2 negative (1)
CASP3 underexpression + BCL2 positive (1)
CD20 expression + PAX5 expression + BCL2 expression (1)
CD22 underexpression + BCL2 overexpression (1)
BCL2 positive + IGH positive (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A2 - Guideline
lisocabtagene maraleucel
Sensitive
:
A2
lisocabtagene maraleucel
Sensitive: A2 - Guideline
lisocabtagene maraleucel
Sensitive
:
A2
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
lenalidomide
Sensitive: B - Late Trials
lenalidomide
Sensitive
:
B
lenalidomide
Sensitive: B - Late Trials
lenalidomide
Sensitive
:
B
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
cytarabine + methotrexate
Resistant: C3 – Early Trials
cytarabine + methotrexate
Resistant
:
C3
cytarabine + methotrexate
Resistant: C3 – Early Trials
cytarabine + methotrexate
Resistant
:
C3
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
rituximab
Resistant: C3 – Early Trials
rituximab
Resistant
:
C3
rituximab
Resistant: C3 – Early Trials
rituximab
Resistant
:
C3
MYC rearrangement + BCL2 rearrangement
Lymphoma
MYC rearrangement + BCL2 rearrangement
Lymphoma
lisocabtagene maraleucel
Sensitive: C3 – Early Trials
lisocabtagene maraleucel
Sensitive
:
C3
lisocabtagene maraleucel
Sensitive: C3 – Early Trials
lisocabtagene maraleucel
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Non-Hodgkin’s Lymphoma
MYC rearrangement + BCL2 rearrangement
Non-Hodgkin’s Lymphoma
ibrutinib
Sensitive: C3 – Early Trials
ibrutinib
Sensitive
:
C3
ibrutinib
Sensitive: C3 – Early Trials
ibrutinib
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Follicular Lymphoma
MYC rearrangement + BCL2 rearrangement
Follicular Lymphoma
Sensitive: C3 – Early Trials
Sensitive
:
C3
Sensitive: C3 – Early Trials
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Follicular Lymphoma
MYC rearrangement + BCL2 rearrangement
Follicular Lymphoma
Sensitive: C3 – Early Trials
Sensitive
:
C3
Sensitive: C3 – Early Trials
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
lenalidomide + zanubrutinib
Sensitive: C3 – Early Trials
lenalidomide + zanubrutinib
Sensitive
:
C3
lenalidomide + zanubrutinib
Sensitive: C3 – Early Trials
lenalidomide + zanubrutinib
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
loncastuximab tesirine-lpyl
Sensitive: C3 – Early Trials
loncastuximab tesirine-lpyl
Sensitive
:
C3
loncastuximab tesirine-lpyl
Sensitive: C3 – Early Trials
loncastuximab tesirine-lpyl
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
Sensitive: C3 – Early Trials
Sensitive
:
C3
Sensitive: C3 – Early Trials
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Lymphoma
MYC rearrangement + BCL2 rearrangement
Lymphoma
AR160
Sensitive: C3 – Early Trials
AR160
Sensitive
:
C3
AR160
Sensitive: C3 – Early Trials
AR160
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: C3 – Early Trials
axicabtagene ciloleucel
Sensitive
:
C3
axicabtagene ciloleucel
Sensitive: C3 – Early Trials
axicabtagene ciloleucel
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
IACS-010759
Sensitive: D – Preclinical
IACS-010759
Sensitive
:
D
IACS-010759
Sensitive: D – Preclinical
IACS-010759
Sensitive
:
D
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
ibrutinib
Resistant: D – Preclinical
ibrutinib
Resistant
:
D
ibrutinib
Resistant: D – Preclinical
ibrutinib
Resistant
:
D
MYC rearrangement + BCL2 rearrangement
Non-Hodgkin’s Lymphoma
MYC rearrangement + BCL2 rearrangement
Non-Hodgkin’s Lymphoma
ibrutinib + alemtuzumab
Sensitive: D – Preclinical
ibrutinib + alemtuzumab
Sensitive
:
D
ibrutinib + alemtuzumab
Sensitive: D – Preclinical
ibrutinib + alemtuzumab
Sensitive
:
D
MYC rearrangement + BCL2 rearrangement
Lymphoma
MYC rearrangement + BCL2 rearrangement
Lymphoma
HZX-02-059
Sensitive: D – Preclinical
HZX-02-059
Sensitive
:
D
HZX-02-059
Sensitive: D – Preclinical
HZX-02-059
Sensitive
:
D
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
venetoclax
Sensitive: D – Preclinical
venetoclax
Sensitive
:
D
venetoclax
Sensitive: D – Preclinical
venetoclax
Sensitive
:
D
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
copanlisib
Sensitive: D – Preclinical
copanlisib
Sensitive
:
D
copanlisib
Sensitive: D – Preclinical
copanlisib
Sensitive
:
D
MYC rearrangement + BCL2 rearrangement
Lymphoma
MYC rearrangement + BCL2 rearrangement
Lymphoma
venetoclax + DUP 785
Sensitive: D – Preclinical
venetoclax + DUP 785
Sensitive
:
D
venetoclax + DUP 785
Sensitive: D – Preclinical
venetoclax + DUP 785
Sensitive
:
D
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
BTM-3566
Sensitive: D – Preclinical
BTM-3566
Sensitive
:
D
BTM-3566
Sensitive: D – Preclinical
BTM-3566
Sensitive
:
D
MYC rearrangement + BCL2 rearrangement
Lymphoma
MYC rearrangement + BCL2 rearrangement
Lymphoma
SGN-CD19B
Sensitive: D – Preclinical
SGN-CD19B
Sensitive
:
D
SGN-CD19B
Sensitive: D – Preclinical
SGN-CD19B
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login